[1] |
Lee SW, Leem CS, Kim TJ, et al. The long-term course of groundglass opacities detected on thin-section computed tomography[J]. Respir Med, 2013,107(6): 904-10.
|
[2] |
Lee KH, Goo JM, Park SJ, et al. Correlation between the size of the solid component on thin-section CT and the invasive component on pathology in small lung adenocarcinomas manifesting as ground-glass nodules[J]. J Thorac Oncol, 2014, 9( 1): 74-82.
|
[3] |
Xu J, Liu CF, Geng LL, et al. Combined score assessment of clinical and imaging features in diagnosis of bronchioloalveolar carcinoma[J]. Zhong Liu Fang Zhi Yan Jiu, 2012, 39(6): 705-9.[徐 健, 刘春芳, 庚俐丽, 等. 临床和影像特征联合评分在细支气 管肺泡癌诊断中的作用评估[J]. 肿瘤防治研究, 2012, 39(6): 70 5-9.]
|
[4] |
Lozano MD, Zulueta JJ, Echeveste JI, et al. Assessment of epidermal growth factor receptor and K-ras mutation status in cytological stained smears of non-small cell lung cancer patients: correlation with clinical outcomes[J]. Oncologist, 2011, 16 (6): 87 7-85.
|
[5] |
Meng D, Yuan M, Li X, et al. Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis[J]. Lung Cancer, 2013, 81(1): 1-10.
|
[6] |
Lin CC, Yang JC. Optimal management of patients with nonsmall cell lung cancer and epidermal growth factor receptor mutations[J].Drugs, 2011, 71(1): 79-88.
|
[7] |
Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib[J]. PLoS Med, 2005, 2(1): e17.
|
[8] |
Wu JY, Shih JY, Chen KY, et al. Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations[J]. Medicine (Baltimore), 2011, 90(3): 159-67.
|
[9] |
Lim HJ, Ahn S, Lee KS, et al. Persistent pure ground-glass opacity lung nodules ≥ 10 mm in diameter at CT scan: histopathologic comparisons and prognostic implications[J]. Chest, 2013, 144(4): 12 91-9.
|
[10] |
Cho S, Yang H, Kim K, et al. Pathology and prognosis of persistent stable pure ground-glass opacity nodules after surgical resection[J]. Ann Thorac Surg, 2013, 96(4): 1190-5.
|
[11] |
Song YS, Park CM, Park SJ, et al. Volume and mass doubling times of persistent pulmonary subsolid nodules detected in patients without known malignancy[J]. Radiology, 2014, 273(1): 27 6-84.
|
[12] |
Wu YL, Fukuoka M, Mok TS, et al. Tumor response and healthrelated quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with firstline gefitinib: post hoc analyses from the IPASS study[J]. Lung Cancer, 2013, 81(2): 280-7.
|
[13] |
Ludovini V, Bianconi F, Pistola L, et al. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer[J]. J Thorac Oncol, 2011, 6(4): 707-15.
|
[14] |
Mao C, Qiu LX, Liao RY, et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies[J]. Lung Cancer, 2010, 69(3): 272-8.
|